NCT04797000 - Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

April 26, 2025

Study Completion Date

December 9, 2026

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Eltrombopag

Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)

DRUG

Placebo

Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)

Trial Locations (20)

286-8523

Novartis Investigative Site, Narita

830-8543

Novartis Investigative Site, Kurume

960 1295

Novartis Investigative Site, Fukushima

739-0696

Novartis Investigative Site, Ohtake

663 8501

Novartis Investigative Site, Nishinomiya

920-8530

Novartis Investigative Site, Kanazawa

259-1193

Novartis Investigative Site, Isehara

221-0855

Novartis Investigative Site, Yokohama

980 8574

Novartis Investigative Site, Sendai

852-8501

Novartis Investigative Site, Nagasaki

589 8511

Novartis Investigative Site, Ōsaka-sayama

113-8603

Novartis Investigative Site, Bunkyo-ku

173 8606

Novartis Investigative Site, Itabashi Ku

750-0061

Novartis Investigative Site, Shimonoseki

030 8553

Novartis Investigative Site, Aomori

260-0852

Novartis Investigative Site, Chiba

500 8513

Novartis Investigative Site, Gifu

860-0008

Novartis Investigative Site, Kumamoto

534-0021

Novartis Investigative Site, Osaka

990 9585

Novartis Investigative Site, Yamagata